Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0EF
- Development stage
- Preclinical
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
SIM0EF is an experimental proteolysis-targeting chimera (PROTAC) developed by Simcere Pharmaceutical (specifically associated with Shandong Simcere Medgenn) for the treatment of autoimmune diseases. It is designed to selectively target and degrade Signal Transducer and Activator of Transcription 4 (STAT4), a transcription factor that plays a critical role in the signaling pathways of cytokines such as IL-12 and IL-23, which are essential for Th1 and Th17 cell differentiation. By utilizing the PROTAC modality, SIM0EF facilitates the ubiquitination and subsequent proteasomal degradation of STAT4, potentially offering a more potent and durable therapeutic effect compared to traditional inhibitors in managing conditions like systemic lupus erythematosus or other inflammatory disorders. The drug is currently in the early stages of development within Simcere's innovative pipeline.
- Other names
- STAT4 PROTACSTAT-4 PROTACSTAT 4 PROTAC
02
Targets
STAT4
Beyond the preview
Go deeper on SIM0EF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0EF.